FL-EIGHT-SLEEP
18.3.2022 17:02:08 CET | Business Wire | Press release
Eight Sleep , the world's first sleep fitness company, today announced that the Mercedes-AMG Petronas Formula 1 Team has named the company as Official Team Supplier in a joint effort to support the team’s preparations for an expansive 2022 Formula 1 schedule. The Mercedes-AMG Petronas team including drivers, Lewis Hamilton, George Russell, as well as Team Principal, Toto Wolff, will have access to Eight Sleep’s suite of products to optimize their sleep and ensure peak performance this and next season.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220318005290/en/
The Mercedes-AMG Petronas F1 Team rigorously looks for ways to improve the performance of the car and the team. Eight Sleep’s next-generation sleep technology is engineered to support the technical and human demands of the intense 2022 F1 schedule, enabling the 8x Champions to maintain their long term success. The Mercedes-AMG Petronas F1 Team joins Eight Sleep along with more than 200 professional athletes who rely on Eight Sleep to power their recovery through the Pod Pro’s advanced thermoregulation and sleep technology.
In addition to Eight Sleep’s branding being featured on the team’s car for the inaugural Miami Grand Prix, the Eight Sleep logo will be featured on all the car covers for the duration of the season. Eight Sleep will support Mercedes-AMG Petronas F1 team members to power their performance through their innovative sleep technology Data has shown that Eight Sleep products help 49% of Eight Sleep members see an increase in their HRV of at least 10% one week after sleeping on the Pod.
With grueling schedules that consist of training, racing, and traveling, it’s critical that team members properly refuel and recover in order to perform their best. When they are pushing their bodies to their limits, in between the training, racing and hectic traveling schedules, the team needs to properly recover and refuel. Eight Sleep’s thermoregulation is designed to recharge the team to peak energy levels, which will be critical for the Mercedes-AMG Petronas Formula One Team in 2022. Additionally, the Eight Sleep App leverages the product’s sensor technology to provide daily reports on key health metrics, such as heart rate, HRV, sleeping stages, and more, giving the team the ability to build better health regimes and optimize their sleep.
“Our team is made up of over 2,000 people across Brackley and Brixworth, all of whom perform at their peak every day in a sport where every single detail matters. To achieve the level of sustained performance that is required to compete in Formula 1, we are relentless in exploring all possible optimizations, including sleep. By partnering with Eight Sleep we are looking to utilize their technology during the upcoming season while also spreading a key message about the importance of recovery when you aim for peak performance,” said Toto Wolff, Team Principal and CEO of the Mercedes-AMG Petronas F1 Team.
“Eight Sleep, and myself personally, are thrilled to partner with Mercedes-AMG Petronas Formula One and power their team’s sleep so they can continue to perform at the highest level,” said Matteo Franceschetti, Co-Founder and CEO of Eight Sleep. “Growing up in Italy, Formula One was a huge part of my life – from racing cars with my father to starting my first business taking pictures of racing cars at local tracks. Mercedes-AMG Petronas F1’s commitment to constant innovation and improvement is what we strive for at Eight Sleep. We will work together to improve the team’s sleep and recovery for a successful win at this year’s Grand Prix races.”
“We’re delighted to welcome Eight Sleep to the team and to start working with them to develop and innovate around our sleep and recovery programmes,” said Richard Sanders, Commercial Director of the Mercedes-AMG Petronas F1 Team. “Eight Sleep’s approach to reimagining sleep is very similar to how we operate. They’re obsessed with performance, the fine details and ensuring our team gets the rest they need to perform at their very best.”
The Pod Pro by Eight Sleep
The Pod Pro by Eight Sleep is the most advanced solution on the market for thermoregulation. The Pod Pro retains vital features of the original and award-winning Pod, introducing new Room Climate and Weather Response, a Comfort Blend™ Integrated Topper, GentleRise™ Wake Up Technology, and double the amount of sensors enabling new Heart Rate Variability monitoring and a Daily Health Check report. The advancements in the Pod Pro help everyone with their rest and recovery – from elite athletes to everyday consumers. The product transforms any ordinary bed into an advanced health platform that fuels both performance and longevity.
Current and former Eight Sleep athletes include Red Gerard (2018 Gold Medalist, Snowboarding), Brooke Wells (Two-time individual CrossFit Gamesathlete), Apolo Ohno (Two-Time Gold Medalist, Speed Skating), Justin Medeiros (CrossFit Champion 2021), Daniel Sturridge (English Soccer Player), Daryl Homer (2020, and 2016 Silver Medalist, Fencing), and Jane Campbell (2020 Bronze Medalist, Soccer). Eight Sleep’s athlete-investors include Alex Rodriguez (retired MLB athlete and entrepreneur), Matthew Dellavedova (2020 Bronze Medalist, Basketball), Kris Bryant (San Francisco Giants outfielder), and J.D. Martinez (Boston Red Sox outfielder).
About Eight Sleep
Eight Sleep is the world's first sleep fitness company with a mission to fuel human potential through optimal sleep. Eight Sleep leverages thermoregulation, data, and technology to restore individuals to their peak energy levels every morning. Eight Sleep was named one of Fast Company's “Most Innovative Companies of 2022” and “Most Innovative Companies of 2018,” and recognized two years in a row by TIME's “Best Inventions of the Year.” To learn more, visit eightsleep.com .
About Mercedes-AMG Petronas Formula One
Mercedes-AMG Petronas Formula One Team is the works team of Mercedes-Benz, competing at the pinnacle of motorsport – the FIA Formula One™ World Championship.
Formula One is like nothing else in the sporting sphere. It’s a demanding technical and human challenge, combining cutting-edge technologies and innovation, high-performance management and elite teamwork.
At Mercedes-AMG Petronas Formula One Team, a group of passionate and determined people work to design, develop, manufacture and race the cars driven by seven-time World Champion Lewis Hamilton and young star George Russell.
The team has set a new benchmark for F1 success during the sport’s current Hybrid era, winning consecutive Drivers’ and Constructors’ World Championships in 2014, 2015, 2016, 2017, 2018, 2019 and 2020, and the Constructors’ Championship in 2021. During those title-winning seasons, the team has scored 111 wins, 232 podium finishes, 118 pole positions, 81 fastest laps and 53 one-two finishes from 160 race starts.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220318005290/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Chiesi Group to Acquire KalVista Pharmaceuticals, Expanding its Global Rare Disease Portfolio29.4.2026 13:42:00 CEST | Press release
Highlights: Chiesi agreed to acquire KalVista Pharmaceuticals for $27.00 per share in cash, representing an equity consideration of approximately $1.9bnAcquisition adds to Chiesi’s rare immunology portfolio the first oral, on-demand therapy for hereditary angioedema, strengthening Chiesi’s long-term commitment to people living with rare conditionsTransaction expected to close in Q3 2026 Chiesi Group (“Chiesi”), an international research-focused biopharmaceutical group and certified B Corp, and KalVista Pharmaceuticals, Inc.(“KalVista”) (Nasdaq: KALV), today announced that the companies have entered into a definitive agreement under which Chiesi will acquire KalVista (the “Transaction”). The Transaction was unanimously approved by both Chiesi’s and KalVista’s Boards of Directors and is expected to close in Q3 2026, subject to the satisfaction of customary closing conditions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/202604
Pacific Defense Awarded U.S. Marine Corps Contract for Next Generation Electronic Warfare Prototype29.4.2026 13:00:00 CEST | Press release
Award advances SOSA/CMOSS mission system ecosystem and informs future EW fielding decisions Pacific Defense has been awarded a 12-month rapid prototyping contract by the U.S. Marine Corps Systems Command (MARCORSYSCOM), Program Manager for Tactical Communications and Electronic Warfare (PM TCE) to support next-generation electronic warfare (EW) capability evaluation. The effort will assess Modular Open Systems Approach (MOSA) Electronic Warfare (EW) mission systems and their potential in modernizing USMC capabilities. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429918712/en/ Pacific Defense's Next Generation Electronic Warfare System enables rapid integration of new hardware and software into a common chassis, accelerating capability insertion while reducing vendor lock and lifecycle costs. Under the contract, Pacific Defense will deliver SOSA/CMOSS-aligned mission systems to enable vehicle-based experimentation by U.S
Visa Accelerates Stablecoin Momentum: Adding Five Blockchains for Settlement29.4.2026 13:00:00 CEST | Press release
Stablecoin settlement pilot sees record growth 50% quarter over quarter, reaching $7B run rate. Today, Visa (NYSE: V) announced that it is adding five blockchains to its global stablecoin settlement pilot, expanding how issuers and acquirers can settle with the network. As stablecoins move into mainstream payment flows, Visa’s stablecoin settlement pilot now supports nine blockchains and has reached a $7 billion annualized stablecoin settlement run rate, up 50% since last quarter. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429143049/en/ Visa is adding support for five additional blockchains, further expanding its multi-chain settlement capabilities. “Our partners are building in a multi-chain world, and they expect their options to reflect that reality,” said Rubail Birwadker, Global Head of Growth Products and Strategic Partnerships, Visa. “Expanding our stablecoin settlement pilot program to more blockchains means o
U.S. FDA Grants Priority Review to BeOne Medicines’ TEVIMBRA in First-Line HER2+ GEA29.4.2026 12:00:00 CEST | Press release
TEVIMBRA plus ZIIHERA and chemotherapy regimen delivered statistically significant median OS of 26.4 months, an unprecedented result in this challenging diseaseResults from the global Phase 3 HERIZON-GEA-01 study demonstrate potential to change clinical practice in advanced HER2+ gastroesophageal adenocarcinoma BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review to a supplemental Biologics License Application (sBLA) for TEVIMBRA® (tislelizumab) in combination with ZIIHERA® (zanidatamab) and chemotherapy for the first-line treatment of unresectable locally advanced/metastatic HER2-positive (HER2) gastric, gastroesophageal junction, or esophageal adenocarcinoma. The FDA has also granted Breakthrough Therapy Designation to the regimen of ZIIHERA in combination with fluoropyrimidine- and platinum-containing chemotherapy, with and without TEVIMBRA, in this indica
European Commission (EC) Approves Henlius and Organon’s POHERDY® (pertuzumab), the First Approved Biosimilar to PERJETA (pertuzumab) in Europe29.4.2026 11:30:00 CEST | Press release
Shanghai Henlius Biotech, Inc. (2696.HK), and Organon (NYSE: OGN) today announced the European Commission (EC) has granted marketing authorization for POHERDY® (pertuzumab) 420 mg/14 mL injection for intravenous use, the first and only approved biosimilar to PERJETA (pertuzumab) in Europe, for all indications of the reference product.1 This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260429686426/en/ “As the first, and currently the only, pertuzumab biosimilar in Europe, the EC’s approval of POHERDY marks an important milestone in expanding access to treatments for patients with certain HER2-positive breast cancers, particularly as breast cancer is the most commonly diagnosed cancer among women in the European Union,” said Joe Azzinaro, Vice President, Global Commercial Lead Biosimilars, at Organon.2,3 “Organon’s growing global portfolio of biosimilars reinforces our ongoing commitment to supporting the sustainability of healt
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
